Emphasis on Treatment (Corticosteroids, Immunosuppressive Agents, and Others); Route of Administration (Oral, Injectables, and Others); Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Others); and Region/Country
The Behcet’s Disease Therapeutics Market was valued at USD 301.5 Million in 2022 and is expected to grow at a CAGR of 5.1% during the forecast period (2023-2030).
Behcet’s Disease Therapeutics is a type of rare disorder that is caused due to inflammation in blood vessels in various parts of the body. Behcet’s disease therapeutics mainly gained prominence in the market due to the rising number of clinical trials for finding better treatments for the disease. For instance, in April 2023, China-based Peking Union Medical College Hospital initiated a clinical trial to evaluate the efficacy and safety of lenalidomide in the treatment of oral ulcers in adult patients with refractory mucosal Behcet’s syndrome. In addition to this, investments in healthcare departments as well as government awareness programs regarding rare diseases have increased significantly in recent years, which are the key factors that are creating opportunities for the market.
AbbVie Inc.; Eisai Co., Ltd.; Ainos Inc.; Amgen Inc.; Mitsubishi Chemical Group Corporation; Bristol-Myers Squibb Company; Sanguine Biosciences; Takeda Pharmaceutical Company Limited; CELLTRION INC.; Cardinal Health are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.
“Amongst treatment, corticosteroids category to witness higher CAGR during the forecast period”
Based on the treatment, the market is segmented into corticosteroids, immunosuppressive agents, and others. The corticosteroids segment dominated the market in the year 2022 owing to the rising cases of severe behcet’s disease. Corticosteroids are commonly used in the treatment of Behçet’s disease to help reduce inflammation and manage symptoms. They work by suppressing the immune system’s inflammatory response. In Behçet’s disease, corticosteroids are typically used during flare-ups to quickly control symptoms such as oral and genital ulcers, skin lesions, and eye inflammation. Thus, among the treatments, corticosteroids are expected to witness a higher CAGR during the forecast period.
“Amongst route of administration, oral category held a significant share in the market in 2022”
Based on the route of administration, the market is segmented into oral, injectables, and others. The oral segment held the maximum share in the global market of behcet’s disease therapeutics in 2022 owing to the rising demand for oral tablets. The oral route of administration is commonly utilized in Behçet’s disease treatment for various medications, including corticosteroids, immunosuppressants, and other therapeutic agents. Oral medications are convenient and easy to administer, making them suitable for long-term management of chronic conditions like Behçet’s disease. For instance, Prednisone and prednisolone are corticosteroids frequently prescribed orally to reduce inflammation during flare-ups of Behçet’s disease. Also, immunosuppressants like azathioprine, methotrexate, cyclosporine, and mycophenolate mofetil are often administered orally to suppress the immune system and prevent recurrent flares. Technological innovations, and market expansion in emerging economies will further drive the growth of this segment in the coming years. Thus, among the route of administration, the oral segment held a significant market share in 2022.
“Amongst distribution channel, retail pharmacies category to witness higher CAGR during the forecast period”
Based on the distribution channel, the market is categorized into hospitals pharmacies, retail pharmacies, and others. The retail pharmacies segment is expected to hold a significant share of the market in the forecast period owing to the increasing prevalence of rare disorders like behcet’s disease. Retail pharmacies also play a significant role in Behçet’s disease treatment by providing access to medications, supporting patients with their prescriptions, and offering valuable counseling and support services. While hospital pharmacies primarily serve patients during inpatient stays or outpatient visits to hospitals, retail pharmacies cater to the broader community, including individuals managing Behçet’s disease as outpatients. Thus, the retail pharmacies category will witness a higher CAGR amongst distribution channels during the forecast period.
“Amongst regions, North America held a significant share in the market in 2022”
North America is dominating the market in the current scenario of 2022 due to the surge in cases of Behcet’s disease, rising healthcare expenditure, and rising initiatives and investments in introducing innovative advancements. For instance, according to the National Library of Medicine in the U.S. 5.2 per 100,000 people are present with the behcet’s disease. Government organizations are initiating rare disease awareness programs for the sake of the growing cases in the region. Thus, amongst regions, North America held a significant share of the market in 2022.
Behcet’s Disease Therapeutics Market Report Coverage
Reasons to buy this report:
Customization Options:
The global behcet’s disease therapeutics market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Market Synopsis
4. Executive Summary
5. Impact Of Covid-19 On The Behcet’s Disease Therapeutics Market
6. Behcet’s Disease Therapeutics Market Revenue (usd Bn), 2020-2030f
7. Market Insights By Treatment
8. Market Insights By Route Of Administration
9. Market Insights By Distribution Channel
10. Market Insights By Region
11. Behcet’s Disease Therapeutics Market Dynamics
12. Behcet’s Disease Therapeutics Market Opportunities
13. Behcet’s Disease Therapeutics Market Trends
14. Demand And Supply-side Analysis
15. Value Chain Analysis
16. Competitive Scenario
17. Company Profiled
18. Disclaimer
Analyzing the historical market, estimating the current market, and forecasting the future market of the global behcet’s disease therapeutics market were the three major steps undertaken to create and analyze the adoption of behcet’s disease therapeutics in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were considered. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the global behcet’s disease therapeutics market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the behcet’s disease therapeutics market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the behcet’s disease therapeutics market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as treatment, route of administration, distribution channel, and regions. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the behcet’s disease therapeutics market. Further, we conducted factor analysis using dependent and independent variables such as treatment, route of administration, distribution channel, and regions of behcet’s disease therapeutics. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, business expansion, and product launches in the behcet’s disease therapeutics market sector across the globe.
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the global behcet’s disease therapeutics market, and market shares of the segments. All the required percentage shares split and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2030 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the global behcet’s disease therapeutics market. Data was split into several segments & sub-segments after studying various parameters and trends in the areas of treatment, route of administration, distribution channel, and regions in the global behcet’s disease therapeutics market.
The current & future market trends of the global behcet’s disease therapeutics market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Q1: What is the current market size and growth potential of the behcet’s disease therapeutics market?
Q2: What are the driving factors for the growth of the behcet’s disease therapeutics market?
Q3: Which segment has the largest share of the behcet’s disease therapeutics market by route of administration?
Q4: What are the emerging technologies and trends in the behcet’s disease therapeutics market?
Q5: Which region will dominate the behcet’s disease therapeutics market?
Q6: Who are the key players operating in the behcet’s disease therapeutics market?
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
